CN Patent

CN117320710A — 用于富马酸酯相关疾病的组合治疗

Assigned to Imcyse SA · Expires 2023-12-29 · 2y expired

What this patent protects

本发明涉及药物制剂(组合或药物组合物或成套药盒)，其包含一个或更多个剂量单位的富马酸酯化合物和免疫原性肽或致耐受性肽，所述免疫原性肽或致耐受性肽包含氧化还原酶基序以及涉及富马酸酯相关疾病或病症的(自身)抗原的NKT细胞表位或MHC II类T细胞表位。本发明还涉及这种药物制剂的医学用途。

USPTO Abstract

本发明涉及药物制剂(组合或药物组合物或成套药盒)，其包含一个或更多个剂量单位的富马酸酯化合物和免疫原性肽或致耐受性肽，所述免疫原性肽或致耐受性肽包含氧化还原酶基序以及涉及富马酸酯相关疾病或病症的(自身)抗原的NKT细胞表位或MHC II类T细胞表位。本发明还涉及这种药物制剂的医学用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117320710A
Jurisdiction
CN
Classification
—
Expires
2023-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Imcyse SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.